Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Alexian Brothers Neurosciences Institute Clinical Research
293
mi
from 43215
Elk Grove Village, IL
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Alexian Brothers Neurosciences Institute Clinical Research
293
mi
from 43215
Elk Grove Village, IL
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Indiana University Department of Neurology
166
mi
from 43215
Indianapolis, IN
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Indiana University Department of Neurology
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Neurological Clinical Research Institute (NCRI) Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Neurological Clinical Research Institute (NCRI) Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Mayo Clinic, Department of Neurology
559
mi
from 43215
Rochester, MN
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Mayo Clinic, Department of Neurology
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Memory Enhancement Center of America, Inc.
473
mi
from 43215
Eatontown, NJ
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Memory Enhancement Center of America, Inc.
473
mi
from 43215
Eatontown, NJ
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Neurological Associates of Albany, P. C.
513
mi
from 43215
Albany, NY
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Neurological Associates of Albany, P. C.
513
mi
from 43215
Albany, NY
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Integrative Clinical Trials, LLC
480
mi
from 43215
Brooklyn, NY
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Integrative Clinical Trials, LLC
480
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
UNC Department of Neurology, Physicians Office Building
278
mi
from 43215
Chapel Hill, NC
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
UNC Department of Neurology, Physicians Office Building
278
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
University Hospitals Case Medical Center, Neurology Clinical Trials Unit
129
mi
from 43215
Cleveland, OH
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
University Hospitals Case Medical Center, Neurology Clinical Trials Unit
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
The Clinical Trial Center, LLC
418
mi
from 43215
Jenkintown, PA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
The Clinical Trial Center, LLC
418
mi
from 43215
Jenkintown, PA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Hospital of the University of Pennsylvania, Department of Neurology
414
mi
from 43215
Philadelphia, PA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Hospital of the University of Pennsylvania, Department of Neurology
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
The Memory Clinic
546
mi
from 43215
Bennington, VT
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
The Memory Clinic
546
mi
from 43215
Bennington, VT
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
University of Virginia
275
mi
from 43215
Charlottesville, VA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
University of Virginia
275
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Rivers Wellness and Research Institute
849
mi
from 43215
Oklahoma City, OK
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Rivers Wellness and Research Institute
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic
1513
mi
from 43215
Salt Lake City, UT
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Neuroscience Research Australia
9457
mi
from 43215
Randwick,
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Neuroscience Research Australia
9457
mi
from 43215
Randwick,
Click here to add this to my saved trials
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Status: Enrolling
Updated:  3/12/2018
Dartmouth Hitchcock Medical Center
609
mi
from 43215
Lebanon, NH
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Status: Enrolling
Updated: 3/12/2018
Dartmouth Hitchcock Medical Center
609
mi
from 43215
Lebanon, NH
Click here to add this to my saved trials
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Status: Enrolling
Updated:  3/12/2018
Stanford Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Status: Enrolling
Updated: 3/12/2018
Stanford Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Alabama -- Department of Neurology/Epilepsy Center
492
mi
from 43215
Birmingham, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Alabama -- Department of Neurology/Epilepsy Center
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
North Alabama Neuroscience Research Associates
409
mi
from 43215
Huntsville, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
North Alabama Neuroscience Research Associates
409
mi
from 43215
Huntsville, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Neurology Clinic PC
529
mi
from 43215
Northport, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Neurology Clinic PC
529
mi
from 43215
Northport, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Barrow Neurological Institute
1661
mi
from 43215
Phoenix, AZ
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Barrow Neurological Institute
1661
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Clinical Trials, Inc.
624
mi
from 43215
Little Rock, AR
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Clinical Trials, Inc.
624
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
UCSD - Thornton Hospital
1953
mi
from 43215
La Jolla, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
UCSD - Thornton Hospital
1953
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Southern California- Keck School of Medicine
1970
mi
from 43215
Los Angeles, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Southern California- Keck School of Medicine
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
West Los Angeles VA Healthcare Center
1982
mi
from 43215
Los Angeles, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
West Los Angeles VA Healthcare Center
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Delta Waves, INC
1159
mi
from 43215
Colorado Springs, CO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Delta Waves, INC
1159
mi
from 43215
Colorado Springs, CO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Colorado Department Of Neurology
1155
mi
from 43215
Denver, CO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Colorado Department Of Neurology
1155
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Florida-Shands/Jacksonville
668
mi
from 43215
Jacksonville, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Florida-Shands/Jacksonville
668
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Miami
992
mi
from 43215
Miami, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Miami
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Lovelace Scientific Resources
876
mi
from 43215
Sarasota, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Lovelace Scientific Resources
876
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
McFarland Clinic, PC
569
mi
from 43215
Ames, IA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
McFarland Clinic, PC
569
mi
from 43215
Ames, IA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Kentucky
154
mi
from 43215
Lexington, KY
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Kentucky
154
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Mid-Atlantic Epilepsy and Sleep Center
320
mi
from 43215
Bethesda, MD
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Mid-Atlantic Epilepsy and Sleep Center
320
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
The Comprehensive Epilepsy Care Center For Children and Adults
411
mi
from 43215
Chesterfield, MO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
The Comprehensive Epilepsy Care Center For Children and Adults
411
mi
from 43215
Chesterfield, MO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Beth Israel Med Ctr
478
mi
from 43215
New York, NY
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Beth Israel Med Ctr
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Asheville Neurology Specialists, PA
304
mi
from 43215
Asheville, NC
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Asheville Neurology Specialists, PA
304
mi
from 43215
Asheville, NC
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Medical University of Ohio at Toledo
117
mi
from 43215
Toledo, OH
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Medical University of Ohio at Toledo
117
mi
from 43215
Toledo, OH
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Oregon Neurology PC
2031
mi
from 43215
Tualatin, OR
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Oregon Neurology PC
2031
mi
from 43215
Tualatin, OR
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
The Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
The Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Medical City Dallas Hospital
904
mi
from 43215
Dallas, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Medical City Dallas Hospital
904
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Neurological Clinic - Texas
906
mi
from 43215
Dallas, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Neurological Clinic - Texas
906
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Memorial Hermann Hospital
995
mi
from 43215
Houston, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Memorial Hermann Hospital
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Virginia Comprehensive Epilepsy Program
278
mi
from 43215
Charlottesville, VA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Virginia Comprehensive Epilepsy Program
278
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
VCU Medical Center
344
mi
from 43215
Richmond, VA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
VCU Medical Center
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Hospital Italiano de Buenos Aires
mi
from 43215
Capital Federal,
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Hospital Italiano de Buenos Aires
mi
from 43215
Capital Federal,
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Minnesota Epilepsy Group
617
mi
from 43215
Saint Paul, MN
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Minnesota Epilepsy Group
617
mi
from 43215
Saint Paul, MN
Click here to add this to my saved trials